ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Mortality"

  • Abstract Number: 0609 • ACR Convergence 2023

    Mortality After Autologous Hematopoietic Stem Cell Transplant for Autoimmune Disease: Do Scleroderma Patients Fare Worse?

    Marina Birck1, Autumn Neville1, Jan Storek2, Harry Atkins3, Marie Hudson4, Ines Colmegna5, Jessie R. Lavoie6, Jun Gao7 and Sasha Bernatsky1, 1Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2University of Calgary, Calgary, AB, Canada, 3Ottawa Hospital Research Institute, Ottawa, ON, Canada, 4McGill University, Montréal, QC, Canada, 5The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 6Health Canada, Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Ottawa, ON, Canada, 7Health Canada, Centre for Regulatory Excellence, Statistics and Trials, Biologic and Radiopharmaceutical Drugs Directorate, Ottawa, ON, Canada

    Background/Purpose: Autologous hematopoietic stem cell transplantation (HSCT) has benefitted some patients with autoimmune disease (AD) but is associated with toxicity and treatment-related mortality. Autologous HSCT…
  • Abstract Number: 1156 • ACR Convergence 2023

    Presentations and Outcomes of Idiopathic Inflammatory Myopathies in Hong Kong

    Iris Tang1, Ho So2, Teresa li3, Vivian Tang4, Chi Ho5 and Roy Ho6, 1Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong, 2Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 3Queen Mary Hospital, Hong Kong, Hong Kong, 4North District Hospital, Hong Kong, Hong Kong, 5Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, 6Queen Elizabeth Hospital, Hong Kong, Hong Kong

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous autoimmune diseases with cutaneous, musculoskeletal, and systemic involvements. The Hong Kong Myositis Registry (MyoHK) was…
  • Abstract Number: 1541 • ACR Convergence 2023

    Neurologic Involvement Does Not Affect Cumulative Survival Rates in Patients with ANCA-associated Vasculitis and Is Less Commonly Associated with Rapidly Progressive Glomerulonephritis in Patients with GPA

    Gatr-alnada Gheriani1 and Petar Lenert2, 1University of Iowa Hospital and Clinics, Tiffin, IA, 2University of Iowa Hospitals and Clinics, Iowa City, IA

    Background/Purpose: The aim of this study was to analyze the incidence of nervous system manifestations in a cohort of patients with Microscopic Polyangiitis (MPA) and…
  • Abstract Number: 2122 • ACR Convergence 2023

    Coronary Calcium and Carotid Artery Stiffness as Predictors of Cardiovascular Events and Mortality in Patients with Rheumatoid Arthritis: A 10-year Prospective Follow-up Study

    Cristina Corrales Selaya1, Nuria Vegas Revenga2, Jose Antonio Parra3, Virginia Portilla4, Ricardo Blanco5, Miguel A Gonzalez-Gay6, Ivan Ferraz Amaro7 and Alfonso Corrales4, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Galdakao- Usansolo, Galdakao, Spain, 3Hospital Universitario Marques de Valdecilla, Santander, Spain, 4Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 6IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, 7Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

    Background/Purpose: The risk of mortality is increased in patients with RA compared to the general population. Different non-invasive surrogate markers of atherosclerosis have been implemented…
  • Abstract Number: 0618 • ACR Convergence 2023

    Incident versus Prevalent Interstitial Lung Disease in Systemic Sclerosis in the EUSTAR Database: Different Disease Phenotypes and Prognosis

    liubov Petelytska1, Arthiha Velauthapillai2, Lorenzo Tofani3, Patricia Carreira4, Giovanna Cuomo5, Eric Hachulla6, Ivan Castellvi7, Radim Becvar8, Alexandra Balbir-Gurman9, Paolo Airò10, Irena Litinsky11, Lesley Ann Saketkoo12, Madelon Vonk13, Jeska de Vries-Bouwstra14, Anna Maria Hoffmann-Vold15, marco Matucci Cerinic16, Oliver Distler17 and Cosimo Bruni17, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 2Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 3Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, 4Hospital Universitario 12 de Octubre, Madrid, Spain, 5Department of Precision Medicine, “Luigi Vanvitelli” University of Campania, Naples, Italy, 6University of Lille, Lille, France, 7Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, 8Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic, 9Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, 10Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, 11Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 12University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, 13Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 14Leiden University Medical Center, Leiden, Netherlands, 15Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 16Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, 17Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

    Background/Purpose: Although 50% of patients with systemic sclerosis (SSc) present with interstitial lung disease (ILD) at baseline, new onset of ILD can also occur later…
  • Abstract Number: 1163 • ACR Convergence 2023

    Anti-melanoma Differentiation Associated Gene 5 (Anti-MDA5) Antibody Dermatomyositis: Clinical Features and Outcome in a Racially Diverse Patient Cohort

    Sai Koyoda1, Dawn Wahezi2, Xianhong Xie3, Anand Kumthekar4, Clement Tagoe3 and Bibi Ayesha5, 1Essen Medical Center, Rahway, NJ, 2Children's Hospital at Montefiore, New Rochelle, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 5Montefiore Medical Center, Bronx, NY

    Background/Purpose: Anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody dermatomyositis typically expresses rapidly progressing interstitial lung disease (RP-ILD) and ulcerative skin lesions, with or without muscle involvement.…
  • Abstract Number: 1542 • ACR Convergence 2023

    The Burden of Multimorbidity in ANCA-Associated Vasculitis: A Cohort Study

    Zachary Wallace1, Xiaoqing Fu2, Shruthi Srivatsan2, Zachary Williams2, Claire Cook2, Jennifer Hanberg2, John Stone3, Hyon K. Choi4 and Yuqing Zhang5, 1Massachusetts General Hospital, Newton, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, 4Massachusetts General Hospital and Harvard Medical School, Lexington, MA, 5Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA

    Background/Purpose: With improvements in the risks of relapse and mortality in ANCA-associated vasculitis (AAV), a better understanding of disease- and treatment-related complications is necessary to…
  • Abstract Number: 2127 • ACR Convergence 2023

    Associations Between Rheumatoid Arthritis, Frailty Status and Mortality in Older Adults with Bladder Cancer

    Maya Swaminathan1, Sarah Holt2, John Gore2, Yaw Nyame2, Jonathan Wright2, George Schade2, Ami Shah3, Jeffrey Sparks4, Una Makris5, Petros Grivas6, Maria Suarez-Almazor7, Sarah Psutka2 and Namrata Singh8, 1University of Washington, Seattle, WA, 2Department of Urology, University of Washington, Seattle, WA, 3Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, 4Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 5UT Southwestern Medical Center and Dallas VA, Dallas, TX, 6Division of Medical Oncology, Dept. of Medicine, UW; Clinical Research Division; Fred Hutchinson Cancer Center, Seattle, WA, 7MD Anderson Cancer Center, Houston, TX, 8University of Washington, Bellevue, WA

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of developing certain cancers, including bladder cancer (Beydon et al. 20231). However, few studies have…
  • Abstract Number: 0644 • ACR Convergence 2023

    Prediction of Stable SSc-ILD Depends on Definition of ILD Progression

    Anna-Maria Hoffmann-Vold1, Liubov Petelytska2, Havard Fretheim1, Trond Mogens Aaløkken3, Mike Becker4, Cathrine Brunborg5, Cosimo Bruni6, Christian Clarenbach7, Phuong Phuong Diep8, Rucsandra Dobrota6, Michael Durheim9, Muriel Elhai10, Thomas Frauenfelder11, Suzana Jordan6, Emily Langballe12, Carina Mihai6, Oyvind Midtvedt1, Oyvind Molberg13 and Oliver Distler6, 1Oslo University Hospital, Oslo, Norway, 2Bogomolets National Medical University, Kyiv, Ukraine, 3Dept of Radiology, Oslo University Hospital, Oslo, Norway, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 5Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, 6Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 7Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, 9Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, 10University Hospital zurich, University of Zurich, Zurich, Switzerland, 11Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 12Universitetet i Oslo, Oslo, Norway, 13Dept of Rheumatology, University Hospital Oslo, Oslo, Norway

    Background/Purpose: Progression of interstitial lung disease (ILD) reduces long-term survival in patients with systemic sclerosis (SSc), and aggressive treatment and tight monitoring should be considered.…
  • Abstract Number: 1166 • ACR Convergence 2023

    Patients with COVID-19 and Polymyositis Inpatient Outcomes and Hospital Cost: Nationwide Inpatient Sample 2020

    Emily He1 and Vaneet Sandhu2, 1Loma Linda University Health, Loma Linda, CA, 2Loma Linda University, Loma Linda, CA

    Background/Purpose: During the COVID-19 pandemic, there were growing concerns regarding the impact of SARS-CoV-2 on not only patients with rheumatic diseases but also the national…
  • Abstract Number: 1622 • ACR Convergence 2023

    Myositis-associated Autoantibodies in Juvenile Myositis Are Associated with Severe Disease Features and Mortality

    Matthew Sherman1, Payam Noroozi Farhad2, Katherine Pak3, Iago Pinal-Fernandez3, Kakali Sarkar2, Megan Neely4, Ira Targoff5, Frederick Miller6, Andrew Mammen7 and Lisa Rider8, 1NIAMS/NIH, Washington, DC, 2Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 3National Institutes of Health, Bethesda, MD, 4Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, 5Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, 6NIH, NIEHS, Chapel Hill, NC, 7NIH, Bethesda, MD, 8NIEHS, NIH, Bethesda, MD

    Background/Purpose: Myositis-associated autoantibodies (MAAs), such as anti-Ro52 autoantibodies (Abs), have been found to be associated with interstitial lung disease (ILD) and worse prognosis in the…
  • Abstract Number: 2128 • ACR Convergence 2023

    Higher Vitamin D Levels Before Methotrexate Start Are Associated with Lower Subsequent Mortality in Rheumatoid Arthritis

    Shahdi Malakooti1, Hinnah Siddiqui2, Brigid Wilson2, Taissa Bej2, Megan O'Mara2, Nora Singer3, Grace McComsey4, Lenche Kostadinova5, Maya Mattar6, David Zidar5 and Donald Anthony7, 1Case Western Reserve University, Cleveland, OH, 2Louis Stokes Cleveland VA Medical Center, Cleveland, OH, 3The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, 4University Hospitals Health System at Case Western Reserve University, Cleveland, OH, 5Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, OH, 6Louis Stokes VA Medical Center, Cleveland, OH, 7Case Western Reserve University, Cleveland VA Medical Center, The MetroHealth System, Cleveland, OH

    Background/Purpose: Vitamin D is an immune-modulating hormone. Low Vitamin D levels have been associated with development of autoimmune disease and higher disease activity in early…
  • Abstract Number: 0645 • ACR Convergence 2023

    Continuous Progressive ILD in Systemic Sclerosis Is Associated with Mortality

    Anna-Maria Hoffmann-Vold1, Liubov Petelytska2, Havard Fretheim1, Trond Mogens Aaløkken3, Mike Becker4, Cathrine Brunborg5, Cosimo Bruni6, Christian Clarenbach7, Phuong Phuong Diep8, Rucsandra Dobrota6, Michael Durheim9, Muriel Elhai10, Thomas Frauenfelder11, Suzana Jordan6, Emily Langballe12, Oyvind Midtvedt1, Carina Mihai6, Oyvind Molberg13 and Oliver Distler6, 1Oslo University Hospital, Oslo, Norway, 2Bogomolets National Medical University, Kyiv, Ukraine, 3Dept of Radiology, Oslo University Hospital, Oslo, Norway, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 5Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, 6Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 7Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, 9Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, 10University Hospital zurich, University of Zurich, Zurich, Switzerland, 11Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 12Universitetet i Oslo, Oslo, Norway, 13Dept of Rheumatology, University Hospital Oslo, Oslo, Norway

    Background/Purpose: We have previously shown that short term progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) is associated with mortality. However, it is…
  • Abstract Number: 1169 • ACR Convergence 2023

    All-cause Mortality and Risk Factors for Death in a Large Multi-center Prospective Registry Cohort of Idiopathic Inflammatory Myositis in China

    Liying Peng1, Peng Yin2, Mucong Li3, Qian Wang4, Yanhong wang1, Shuang Zhou4, chanyuan wu4, Jiuliang zhao1, Dong xu5, Mengtao Li3 and xiaofeng Zeng4, 1Peking Union Medical College, Beijing, China, 2Chinese Center for Disease Control and Prevention, Beijing, China, 3Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 4Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 5Peking Union Medical College Hospital, Beijing, China

    Background/Purpose: Our study depicted the mortality and independent risk factors of IIM patients in a large multi-center prospective registry cohort in China. Methods: Patients registered…
  • Abstract Number: 1699 • ACR Convergence 2023

    Immunosuppression with Targeted Therapies Reduces Morbidity and Mortality in Pre-Capillary Pulmonary Hypertension Associated with Systemic Sclerosis: A EUSTAR Analysis

    Cosimo Bruni1, Havard Fretheim2, Lorenzo Tofani3, Yannick Weber1, Eric Hachulla4, Patricia Carreira5, Dilia Giuggioli6, Paolo Airò7, Elise Siegert8, Ulf Müller-Ladner9, marco Matucci Cerinic10, Gabriela Riemekasten11, Carmen Pilar Simeon-Aznar12, Jeska de Vries-Bouwstra13, Lesley Ann Saketkoo14, Joerg Distler15, Alexandra Balbir-Gurman16, Ivan Castellvi17, Elisabetta Zanatta18, Vanessa Smith19, Christopher Denton20, Britta Maurer21, Alessandro Giollo18, Florenzo Iannone22, Lorenzo Dagna23, Marie-Elise Truchetet24, Masataka Kuwana25, Yannick ALLANORE26, Yoshiya Tanaka27, Mickael Martin28, Edoardo Rosato29, Ana Maria Gheorghiu30, Francesco Del Galdo31, Kamal Solanki32, Alessandra Vacca33, CATARINA RESENDE34, SUSANA VIEIRA35, Laszlo Czirjak36, Marko Barisic37, Francesco Paolo Cantatore38, valeria Riccieri39, Kristofer Andréasson40, Lorinda Chung41, Carolina Muller42, Daniela OPRIS-BELINSKI43, Simona Rednic44, Petros Sfikakis45, Yair Levy46, Anna Maria Hoffmann-Vold47, Oliver Distler1, Vivien Hsu48, Stefan Heitmann49, Gianluca Moroncini50, Michele Iudici51, Joerg Henes52, Ellen De Langhe53, Ariane Herrick54 and Carlomaurizio Montecucco55, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2Oslo University Hospital, Oslo, Norway, 3Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, 4University of Lille, Lille, France, 5Hospital Universitario 12 de Octubre, Madrid, Spain, 6Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, 7Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, 8Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, 9Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, 10Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, 11University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, 12Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, 13Leiden University Medical Center, Leiden, Netherlands, 14University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, 15Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, 16Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, 17Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, 18Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, 19Ghent University Hospital, Gent, Belgium, 20University College London, London, United Kingdom, 21University Hospital Bern, University Bern, Bern, Switzerland, 22Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, 23Ospedale San Raffaele, Milano, Italy, 24Bordeaux University Hospital, Bordeaux, France, 25Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 26Université Paris Cité, Paris, France, 27University of Occupational and Environmental Health, Kitakyushu, Japan, 28Department of Internal Medicine, INSERM U1313, Poitiers University, Poitiers University Hospital, Poitiers, France, 29Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy, 30Department of Internal Medicine and Rheumatology, Ion Cantacuzino Clinical Hospital, Bucharest, Romania, 31University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, 32Department of Rheumatology, Te Whatu Ora Health New Zealand Waikato, Hamilton, New Zealand, 33II Chair of Rheumatology, University of Cagliari-Policlinico Universitario, Monserrato, Italy, 34Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Lisboa, Portugal, 35Hospital Fernando Fonseca, Lisbon, Portugal, 36Dept. Rheumatol Immunol, Medical School, university of Pecs, Pecs, Hungary, 37Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia, 38Rheumatology Clinic – Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, 39Department of Clinical, Internal and Cardiovascular Specialities, Sapienza University of Rome, Roma, Italy, 40Lund University, Lund, Sweden, 41Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, 42Federal University of Parana, CURITIBA / PR, Brazil, 43Saint Mary Hospital, Bucharest, Romania, 44Prof Dr Simona Rednic, Cluj, Romania, 45National Kapodistrian University of Athens Medical School, Athens, Greece, 46Meir Medical Center, Autoimmune Research Laboratory, Kfar-Saba, Israel, 47Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 48Rutgers-RWJ Medical School, South Plainfield, NJ, 49Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199, Stuttgart, Germany, 50Marche Polytechnic University, Ancona, Italy, 51Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, 52University Hospital Tuebingen, Tuebingen, Germany, 53Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium, 54University of Manchester, Salford, United Kingdom, 55Unità Operativa e Cattedra di Reumatologia, IRCCS Policlinico S Matteo, Pavia, Italy

    Background/Purpose: Systemic sclerosis (SSc) associated pre-capillary pulmonary hypertension (precapPH) is a severe condition that requires prompt treatment. Although immunosuppressants (IMS) are standard of care for…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology